Deucravacitinib: A Safe and Effective Choice for Treating Psoriasis

Discover groundbreaking insights from the Poetyk Pso study, unveiled at the EADV Congress by Bristol Myers Squibb, showcasing the enduring effectiveness and safety of deucravacitinib in addressing moderate to severe plaque psoriasis over a three-year period. Dr. April Armstrong, lead investigator of the POETYK PSO program, endorses deucravacitinib as the preferred oral treatment for adults, underlining its impressive long-term efficacy and established safety profile. With robust clinical response rates at the 148-week mark, including 73.2% for PASI 75, 48.1% for PASI 90, and 54.1% for sPGA 0/1, this innovative approach stands as a promising solution for individuals globally impacted by psoriasis. Explore the comprehensive safety and efficacy analysis involving 1,519 patients, confirming deucravacitinib’s positive impact and potential to address the unmet needs of over 100 million individuals worldwide facing moderate to severe psoriasis and associated comorbidities.

Read the article »